European guideline for the management of genital herpes, 2010

Patel, Raj; Alderson, S.G.; Geretti, Anna María; Nilsen, Arvid; Foley, Elizabeth; Lautenschlager, S.; Green, J.; Meijden, Willem van der; Gomberg, M.A.; Moi, Harald

doi:10.1258/ijsa.2010.010278

Cited by 64 publications

(54 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In real-life, we expect a lower performance of the test. We will discuss our test results, based on published guidelines for the management and laboratory diagnosis of genital herpes [16, 17]. …”

Section: Methodsmentioning

confidence: 99%

Seroprevalence and correlates of herpes simplex virus type 2 infection among young adults in Arkhangelsk, Northwest Russia: a population-based cross-sectional study

et al. 2016

View full text Add to dashboard Cite

BackgroundHerpes simplex virus type 2 (HSV-2) infection is the most common cause of genital ulcer disease (GUD) worldwide. Mother to child transmission causes high morbidity and mortality among infants. Russia is on the brink of a generalized HIV-epidemic, but Arkhangelsk is still a low-prevalence area. HSV-2 infection is associated with a three-fold increased risk of HIV-infection. The evidence on the seroprevalence of HSV-2 in Russia is limited. The aim of this study was to assess HSV-2 seroprevalence and correlates among young adults in the city of Arkhangelsk.Methods1243 adults aged 18-39 years participated in a cross-sectional population-based study, recruited by a public opinion agency applying a quota sampling method to achieve a data set with similar age- and sex-distribution as the population in Arkhangelsk. All participants completed a standardized, self-administrated questionnaire and were tested for HSV-2. Associations between HSV-2 seropositivity and selected sociodemographic and behavioral factors, and self-reported history of sexually transmitted infections (STIs) were studied by multivariable logistic regression.ResultsHSV-2 seroprevalence was 18.8 %: 12.2 % (95 % confidence interval, CI 9.7-15.2) among men and 24.0 % (95 % CI 20.1-27.3) among women. Among men, HSV-2 positivity was associated with being divorced/widowed (OR = 2.85, 95 % CI 1.06-7.70), cohabitation (OR = 2.45, 95 % CI 1.07-5.62), and a history of STIs (OR = 2.11, 95 % CI 1.14-3.91). In women, HSV-2 positivity was associated with high income (OR = 3.11, 95 % CI 1.45-6.71) and having a lifetime number of sexual partners between 2 and 5 (OR = 2.72, 95 % CI 1.14-6.51), whereas sexual debut at age 18 years or older was inversely associated with the outcome (OR = 0.47, 95 % CI 0.31-0.72). In both sexes, increasing age was the strongest correlate of HSV-2 seropositivity in multivariable analyses.ConclusionThe HSV-2 seroprevalence was twice as high in women than in men and increased with age in both sexes, and similar to that reported from high-prevalence countries in Europe and the USA. The high prevalence of HSV-2 among women in childbearing age reveals the potential for HSV-2 transmission from mothers to infants and increased risk of acquisition HIV-infection; it also contributes to the burden GUD among both sexes. This emphasizes the public health implications of the HSV-2 epidemic in an urban population in North-West Russia.

show abstract

Section: Methodsmentioning

confidence: 99%

Seroprevalence and correlates of herpes simplex virus type 2 infection among young adults in Arkhangelsk, Northwest Russia: a population-based cross-sectional study

et al. 2016

View full text Add to dashboard Cite

show abstract

“…119 Type-specific HSV-2 serology that uses glycoprotein G2 antigen are commercially available, although there are concerns regarding test performance in different populations with varying HSV-2 prevalence. 90,120 Some experts have advocated HSV-2 serology testing among those at high risk of acquiring HIV. 119 However, the benefits of HSV-2 serological testing remain unclear.…”

Section: 113mentioning

confidence: 99%

Australian sexually transmissible infection and HIV testing guidelines for asymptomatic men who have sex with men 2014: a review of the evidence

et al. 2014

View full text Add to dashboard Cite

Abstract.Men who have sex with men (MSM) in Australia and overseas are disproportionately affected by sexually transmissible infections (STIs), including HIV. Many STIs are asymptomatic, so regular testing and management of asymptomatic MSM remains an important component of effective control. We reviewed articles from January 2009-May 2013 to inform the 2014 update of the 2010 Australian testing guidelines for asymptomatic MSM. Key changes include: a recommendation for pharyngeal chlamydia (Chlamydia trachomatis) testing, use of nucleic acid amplification tests alone for gonorrhoea (Neisseria gonorrhoeae) testing (without gonococcal culture), more frequent (up to four times a year) gonorrhoea and chlamydia testing in sexually active HIV-positive MSM, time required since last void for chlamydia first-void urine collection specified at 20 min, urethral meatal swab as an alternative to first-void urine for urethral chlamydia testing, and the use of electronic reminders to increase STI and HIV retesting rates among MSM.

show abstract

“…По данным лите-ратуры, она эффективна у 70-80% пациентов. Для такой терапии обязательным является индивидуа-лизированный подход, который включает оценку частоты, тяжести обострений у данного пациента, а также его индивидуальные потребности в контроле рецидивов заболевания [7][8][9].…”

Section: клиническая дерматология и венерология 3 2015unclassified

“…В случае, если у пациента с дан-ным заболеванием количество рецидивов не превы-шает 10 раз в год, суточная доза валацикловира должна составлять 500 мг. При количестве рециди-вов более 10 в год используется суточная дозировка валацикловира 1000 мг [7][8][9].…”

Section: клиническая дерматология и венерология 3 2015unclassified

Recurrent herpes virus infection: the strategy of antiviral therapy

Shulzhenko¹,

Zuykova²,

Зуйкова³

2015

Klin. dermatol. venerol.

View full text Add to dashboard Cite

Спектр клинических проявлений герпес-ви-русной инфекции (ГВИ) отличается значитель-ным разнообразием. Они зависят от локализации патологического процесса, его распространенно-сти, состояния противовирусного звена иммунно-го ответа. Вирусы простого герпеса 1-го и 2-го ти- Генитальная форма герпес-вирусной инфекции широко распространена и встречается во всех популяционных группах. Самая высокая заболеваемость зарегистрирована у лиц в репродуктивном возрасте, что в значительной мере влияет на материнскую заболеваемость, рождаемость, перинатальные потери и на здоровье нации в целом. Цель исследования -изучение клинической эффективности Валвира (генерического валацикловира компании «Actavis») в терапии генитальной формы хронической рецидивирующей герпесвирусной инфекции (ХРГВИ). Материал и методы. В 2014 г. в клинике Института иммунологии Федерального медико-биологического агентства России проведено сравнительное исследование клинической эффективности препарата Валвир в лечениии иммунокомпетентных пациентов с генитальной формой ХРГВИ. Пациентам основной группы (20 мужчин и женщин) был назначен препарат валацикловир (Валвир), больным группы сравнения (20 человек) -Ацикловир (производство России). Результаты. На фоне 5-дневного курса терапии Валвиром в дозе по 500 мг 2 раза в сутки у пациентов с генитальной формой ХРГВИ отмечено сокращение длительности течения рецидива и ускорение реэпителизации (в среднем с 6,4 сут до лечения до 3,8 сут на фоне терапии), эффективное купирование местных симптомов рецидива (до 2,5±0,3 сут) и сокращение периода начала эпителизации герпетических повреждений (до 1,9 сут) по сравнению с контрольной группой, получавшей ацикловир. Выводы. Валвир -препарат с доказанной клинической эффективностью в отношении генитальной формы ХРГВИ. Показано сокращение продолжительности местных симптомов рецидива и периода реэпителизации. Препарат Валвир обладает хорошей переносимостью и безопасностью как у молодых пациентов, так и пациентов старшего возраста. Ключевые слова: герпетическая инфекция, приверженность лечению, Валвир.The genital form of the herpes virus infection is widespread and occurs in all population groups.The highest herpes incidence rate is recorded in people of the reproductive age, which significantly affects the maternal incidence, birth rate, perinatal losses, and nation's health in general. Aim. The aim was to study the clinical efficacy of Valvir (generic valacyclovir produced by Actavis) in the therapy of the genital form of chronic recurrent herpes viral infection (CRHVI). Material and methods. In 2014, a comparative trial the clinical efficacy of Valvir in treatment of immunocompetent patients with the genital form of CRHVI was conducted at the clinic of the Iimunology Institute, Federal Medical and Biological Agency of Russia. Patients of the main group (20 males and females) were administered valacyclovir (Valvir), and patients of the control group (20 persons) were administered Acyclovir (produced in Russia). Results. On the background of five day Valvir therapy at the dose of 5...

show abstract

European guideline for the management of genital herpes, 2010

Cited by 64 publications

References 84 publications

Seroprevalence and correlates of herpes simplex virus type 2 infection among young adults in Arkhangelsk, Northwest Russia: a population-based cross-sectional study

Seroprevalence and correlates of herpes simplex virus type 2 infection among young adults in Arkhangelsk, Northwest Russia: a population-based cross-sectional study

Australian sexually transmissible infection and HIV testing guidelines for asymptomatic men who have sex with men 2014: a review of the evidence

Recurrent herpes virus infection: the strategy of antiviral therapy

Contact Info

Product

Resources

About